Anti-Inflammatory and Immunomodulatory Effects of 2-(3-Acetyl-5-(4-Chlorophenyl)-2-Methyl-1H-Pyrrol-1-yl)-3-Phenylpropanoic Acid

<b>Background:</b> The pursuit of novel anti-inflammatory agents with enhanced efficacy and safety is crucial. Pyrrole-containing compounds, integral to many NSAIDs, exhibit promising anti-inflammatory properties. Compound <b>3f</b> (2-(3-acetyl-5-(4-chlorophenyl)-2-methyl-1<i>H</i>-pyrrol-1-yl)-3-phenylpropanoic acid), a pyrrole derivative structurally inspired by the COX-2 selective inhibitor celecoxib, was evaluated for its anti-inflammatory and immunomodulatory effects. <b>Methods</b>: Anti-inflammatory activity was assessed in a carrageenan-induced paw edema model in Wistar rats. Compound <b>3f</b> was administered intraperitoneally at 10, 20, and 40 mg/kg, either as a single dose or daily for 14 days. Diclofenac (25 mg/kg) served as the reference. Edema volume was measured by plethysmometry. Systemic inflammation was induced by lipopolysaccharide (LPS), and serum levels of the pro-inflammatory cytokine TNF-α and anti-inflammatory cytokines IL-10 and TGF-β1 were quantified by ELISA following single and repeated administration of compound <b>3f</b>. <b>Results:</b> Single-dose administration of compound <b>3f</b> at 20 mg/kg significantly reduced paw edema at 2 h (<i>p</i> = 0.001). After 14 days, all tested doses significantly inhibited paw edema at all time points (<i>p</i> < 0.001). In the LPS-induced systemic inflammation model, repeated treatment with 40 mg/kg of compound <b>3f</b> significantly decreased serum TNF-α (<i>p</i> = 0.032). TGF-β1 levels increased significantly after both single and repeated doses (<i>p</i> = 0.002 and <i>p</i> = 0.045, respectively), while IL-10 levels remained unaffected. <b>Conclusions:</b> Compound <b>3f</b> exhibits potent anti-inflammatory activity, particularly after repeated dosing, reflected by reduced local edema and systemic TNF-α suppression. The marked elevation of TGF-β1 indicates a potential immunomodulatory mechanism, selectively modulating cytokine profiles without altering IL-10. These findings support compound <b>3f</b> as a promising candidate for targeted anti-inflammatory therapy involving cytokine regulation.